CAR-T Cell Therapy: FDA-Approved Treatment Access Worldwide
Blood Cancer Treatment Coordination | 40-80% Response Rates in Clinical Trials | Hospital Matching Service for USA, China & Europe
Active Clinical Trials Globally
FDA-Approved CAR-T Products
Hospital Access Countries
Interactive Eligibility Assessment
Complete our 4-step questionnaire to understand potential CAR-T therapy options
What type of cancer do you have?
Partner Hospital Comparison
JCI-accredited hospitals with published CAR-T outcome data
| Country | Hospital | List Price | Wait Time | Success Rate* | English Support |
|---|---|---|---|---|---|
| China | Beijing Tongren Hospital | $150-200K | 2-3 weeks | 85-89%* CR rate in published trials |
✅ Full team |
| China | Tianjin Cancer Hospital | $180-250K | 2-4 weeks | 82-88%* CR rate in published trials |
✅ Translators |
| USA | MD Anderson | $450-550K | 10-14 weeks | 80-86%* CR rate in published trials |
✅ Native |
Trial Data vs Real-World Outcomes
Published clinical trial results with realistic expectations
B-cell ALL (Acute Lymphoblastic Leukemia)
- Overall Response Rate (ORR): 80-90% (Phase II trial data)
- Complete Response (CR): 60-80% (selected patients)
- Source: ELIANA trial (n=75), ZUMA-3 (n=55)
- Reality: 25% relapse within 12 months
DLBCL (Large B-cell Lymphoma)
- ORR: 50-70% (real-world data)
- CR: 40-54%
- Source: SCHOLAR-1, ZUMA-12 (n=180)
- Reality: 40-50% of patients don't respond initially
⚠️ Experimental Phase I/II Only
Gastric Cancer (Claudin 18.2): ORR 33-48%, CR 5-10% (Chinese trials, n=40)
General Challenges: Tumor microenvironment suppression, antigen heterogeneity, limited CAR-T trafficking
Complete Side Effects Disclosure
Understanding treatment risks is critical to informed decision-making
Common Side Effects
- Cytokine Release Syndrome (CRS): 70-90% of patients, Grade 3-4 in 10-25%
- Neurotoxicity (ICANS): 20-60%, Grade 3-4 in 10-20%
- Infections: 30-50% require hospitalization
- Prolonged Cytopenias: 30-40%, can last 3+ months
JCI-Accredited Partner Hospitals
Hospitals meeting our strict partner criteria
Beijing Tongren Hospital
Accreditation: JCI + NMPA approved
Products: Relma-cel, Cilta-cel, Clinical trials
View Hospital ProfileMD Anderson Cancer Center
Accreditation: FDA center + JCI
Products: All 7 FDA products available
View Hospital ProfileWhat We Coordinate (5-Step Process)
Step 1
Records Review
24-hour review, no cost or obligation
Step 2
Specialist Matching
48-hour specialist response
Step 3
Travel Planning
3-5 day visa processing
Step 4
Treatment Begins
2-4 weeks from arrival
Step 5
Follow-up Care
Lifetime coordination support
⚠️ Important Legal Distinction
✅ WHAT WE COORDINATE: Hospital appointments, medical record translation, visa assistance, travel logistics, interpreters.
❌ WHAT WE DON'T DO: Medical diagnosis, treatment decisions, guarantee outcomes, provide medical advice.
We are a medical tourism coordination service. All medical decisions are made by licensed physicians at accredited hospitals.
Data-Driven Case Studies
Representative cases from our coordination experience
Case 1: B-cell ALL Patient
Profile: Age 45, Male, 3rd relapse, ECOG 1
Treatment: CD19 CAR-T (Relma-cel) in Shanghai
✅ Complete Response
MRD Negative at Day 28
18 months remission ongoing
Case 2: DLBCL Patient
Profile: Age 58, Female, refractory, ECOG 2
Treatment: CD19 CAR-T in Beijing
⚠️ Partial Response
60% tumor reduction
Required additional therapy
Frequently Asked Questions
Relapsed/refractory patients (2+ failed lines) are primary candidates. Eligibility also depends on organ function, performance status, and specific cancer type. Upload records for specialist review.
Products like Carvykti are FDA-approved and manufactured to same standards globally. China's NMPA has similar approval processes. Price differences reflect lower labor costs and government subsidies.
Severe CRS protocol includes immediate ICU transfer, Tocilizumab administration, and supportive care. All partner hospitals have 24/7 ICU with CRS experience. Mortality rate from Grade 4 CRS: 5-10%.
CAR-T Therapy Content Navigation Tree
Explore our comprehensive CAR-T therapy resources organized by topic
Complete Resource Library
Our CAR-T therapy content is organized into a comprehensive tree structure to help you find exactly what you need:
Educational Resources
Detailed guides on CAR-T mechanism, manufacturing process, and clinical trial data.
Hospital Information
Complete profiles of partner hospitals including accreditation, success rates, and services.
Financial Guidance
Cost breakdowns, insurance navigation, and financial assistance programs.
Ready to Explore CAR-T Therapy Options?
Contact our coordination team for a free eligibility review and hospital matching service.
12 Responses